mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio

Oncotarget. 2012 Dec;3(12):1491-2. doi: 10.18632/oncotarget.799.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Adaptor Proteins, Signal Transducing / metabolism*
  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Biomarkers, Tumor / metabolism*
  • Drug Design
  • Eukaryotic Initiation Factor-4E / metabolism*
  • Humans
  • Molecular Targeted Therapy*
  • Neoplasms / drug therapy*
  • Neoplasms / enzymology
  • Neoplasms / pathology
  • Protein Kinase Inhibitors / therapeutic use*
  • Signal Transduction / drug effects
  • TOR Serine-Threonine Kinases / antagonists & inhibitors*
  • TOR Serine-Threonine Kinases / metabolism

Substances

  • Adaptor Proteins, Signal Transducing
  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Eukaryotic Initiation Factor-4E
  • Protein Kinase Inhibitors
  • TOR Serine-Threonine Kinases